BIOCRYST PHARMACEUTICALS, INC.
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1986-01-01
- Employees
- 536
- Market Cap
- $1.7B
- Website
- http://www.biocryst.com
A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency
- Conditions
- Interventions
- First Posted Date
- 2011-08-02
- Last Posted Date
- 2013-11-20
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT01407874
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol
- Conditions
- Interventions
- First Posted Date
- 2010-12-23
- Last Posted Date
- 2013-11-20
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 279
- Registration Number
- NCT01265264
A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.
- First Posted Date
- 2010-10-20
- Last Posted Date
- 2015-01-06
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 1
- Registration Number
- NCT01224795
Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout
- First Posted Date
- 2010-05-25
- Last Posted Date
- 2012-01-23
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 87
- Registration Number
- NCT01129648
Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout
- First Posted Date
- 2009-09-28
- Last Posted Date
- 2012-01-23
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 99
- Registration Number
- NCT00985127
- Locations
- ๐บ๐ธ
Selah Medical Center, Boise, Idaho, United States
๐บ๐ธTriangle Medical Research Associates, Raleigh, North Carolina, United States
๐บ๐ธCarolinas Center for Rheumatology & Arthritis, Rock Hill, South Carolina, United States
A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza
- Conditions
- Interventions
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2015-02-12
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 405
- Registration Number
- NCT00958776
- Locations
- ๐ฎ๐ณ
Fortis Escort Hospital, Jaipur, Rajasthan, India
๐บ๐ธWashington Hospital Center CAR, Washington, District of Columbia, United States
๐บ๐ธKentucky Lung Clinic, Hazard, Kentucky, United States
Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza
- Conditions
- Interventions
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2015-02-12
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 234
- Registration Number
- NCT00957996
A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza
- Conditions
- Interventions
- First Posted Date
- 2008-06-26
- Last Posted Date
- 2015-02-16
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 405
- Registration Number
- NCT00705406
- Locations
- ๐บ๐ธ
Mercury Street Medical Group, PLLC, Butte, Montana, United States
๐บ๐ธWest Houston Clinical Research, Houston, Texas, United States
๐ฆ๐บHoldsworth House Medical Practice, Darlinghurst, Australia
Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)
- Conditions
- First Posted Date
- 2008-03-21
- Last Posted Date
- 2012-01-23
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 23
- Registration Number
- NCT00640523
- Locations
- ๐บ๐ธ
UCLA Medical Center, Los Angeles, California, United States
๐บ๐ธWashington University School of Medicine, St. Louis, Missouri, United States
๐บ๐ธWeill Cornell Medical College, New York, New York, United States
Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza
- First Posted Date
- 2008-02-08
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 82
- Registration Number
- NCT00610935
- Locations
- ๐บ๐ธ
Clopton Clinic, Jonesboro, Arkansas, United States
๐บ๐ธKevin Adkins, MD, Mountain Home, Arkansas, United States
๐บ๐ธIntegrated Medical Research PC, Ashland, Oregon, United States